FMP
Idera Pharmaceuticals, Inc.
IDRA
NASDAQ
Inactive Equity
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
0.425 USD
-0.1272 (-29.93%)
About
ceo
Mr. Vincent J. Milano
sector
Healthcare
industry
Biotechnology
website
https://www.iderapharma.comexchange
NASDAQ
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
CIK
0000861838
ISIN
US45168K4058
CUSIP
45168K405
Address
505 Eagleview Boulevard
Phone
484 348 1600
Country
US
Employee
13
IPO Date
Jan 25, 1996
Key Executives
